Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem zaawansowany rak płuc (rozprzestrzeniony na inne narządy)
- •Obecna mutacja w genie EGFR (mutacja exon 19 lub L858R)
- •Możliwość połykania tabletek
- •Spodziewana długość życia powyżej 3 miesięcy
- •Prawidłowe wyniki podstawowych badań krwi (białe krwinki, płytki, hemoglobina)
- •Prawidłowa funkcja wątroby i nerek
- •Jeśli pacjent ma wirusowe zapalenie wątroby B, wirus musi być kontrolowany lekami
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Ohio State University Comprehensive Cancer Center
Columbus, United States
Trial contact
The Ohio State University Comprehensive Cancer Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.